Gabapentin
Product Images NDC 53217-243

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 53217-243). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Gabapentin Usp 800mg 1)

Image (Gabapentin Usp 800mg 1)
The table shows the recommended daily dose of gabapentin for patients with different levels of renal function, based on their creatinine clearance rate. The dosage ranges from 900 to 1200 mg/day for patients with a creatinine clearance rate of 60 mL/min or greater, to 100 to 700 mg/day for patients with a creatinine clearance rate less than 30 mL/min. Patients on hemodialysis should receive maintenance doses based on the upper portion of the table and also a post-hemodialysis supplemental dose every four hours according to the lower portion of the table. Different abbreviations are provided for the frequency of the doses: TID (three times a day), BID (two times a day), and QD (a single daily dose).*
FDA Label Image

Image (Gabapentin Usp 800mg 2)

FDA Label Image

Image (Gabapentin Usp 800mg 3)

Image (Gabapentin Usp 800mg 3)
This appears to be a table showing the Risk by Indication for Antiepileptic Drugs in the Pooled Analysis. The table shows the indications for epilepsy, psychiatry and other, as well as the total count of patients. The data presents the risk of events per 1000 patients for both Placebo patients and those given drug patents, along with relative risk and risk difference between the two groups.*
FDA Label Image

Image (Gabapentin Usp 800mg 4)

FDA Label Image

Image (Gabapentin Usp 800mg 5)

Image (Gabapentin Usp 800mg 5)
The text describes a graph or chart showing the mean pain score during different weeks of a study. The study consisted of a 4-week dose titration period followed by a fixed dose period. The graph shows the mean pain score for both the placebo group and a group of participants taking 3600 mg/day of gabapentin. The graph shows weeks 1-8, including the baseline measurement.*
FDA Label Image

Image (Gabapentin Usp 800mg 6)

FDA Label Image

Image (Gabapentin Usp 800mg 7)

Image (Gabapentin Usp 800mg 7)
The text provides a figure (Figure 3) showing the proportion of responders in controlled studies for the treatment of post-herpetic neuralgia (PHN). The results suggest that patients with a greater than 50% reduction in pain score were achieved in Study 1 (34%), Study 2 (40%), and Study 3 (50%). The statistical significance reported for Study 1 and 2 is p<0.001. There is also information related to different treatments (GEP 3600, GBP 1800, and GBP 2400), but without sufficient context, it is not possible to provide a useful interpretation.*
FDA Label Image

Image (Gabapentin Usp 800mg 8)

FDA Label Image

Image Description (Gabapentin Usp 800mg 9)

Image Description (Gabapentin Usp 800mg 9)
This is a description of a Gabapentin medication package, with details such as the NDC number, tablet size, and concentration indicated. The medication is manufactured by Invagen Pharmaceuticals and is used to treat seizures and nerve pain. The package contains 30 tablets.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.